SYNCOMFPharmaceuticals
Syncom Formulations India Ltd — PE Ratio & Valuation Analysis
₹10.30
-5.36%
Current P/E23.28xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E47.6x51.1% below avg
✅
26.7% Discount to Industry
SYNCOMF P/E 23.28x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2025 | ₹0.57 | ₹14 | 25x |
| 2024 | ₹0.34 | ₹20 | 58.8x |
| 2023 | ₹0.22 | ₹15 | 69.6x |
| 2022 | ₹0.24 | ₹9 | 36.9x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Syncom Formulations India Ltd Valuation
Syncom Formulations India Ltd (SYNCOMF) currently trades at 23.28x earnings. The Pharmaceuticals sector average PE is 31.77x. SYNCOMF is trading at a discount to peers — may indicate relative value. Historically, SYNCOMF has traded at an average PE of 47.6x — it is currently below that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
15.50%
Dividend Yield
0.00%
More on Syncom Formulations India Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.